 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Efficacy of pembrolizumab in classic or endemic Kaposi's sarcoma

Lancet Oncol: Efficacy of pembrolizumab in classic or endemic Kaposi's sarcoma

 Last Update: 2022-04-22
 Source: Internet
 Author: User

Tags

1 8 channel

pens treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

While the treatment of iatrogenic and HIV-related Kaposi's sarcoma is well established and is primarily based on restoring immune function, the treatment of classical and endemic Kaposi's sarcoma is not well established
.

Chemotherapy or interferon alfa are used in patients with extensive cutaneous or visceral Kaposi's sarcoma, but may be poorly tolerated and fewer patients achieve long-term remission

The aim of this study was to evaluate the therapeutic activity of pembrolizumab in classical and endemic Kaposi's sarcoma requiring systemic therapy
.

Therapeutic activity of pembrolizumab in classical and endemic Kaposi sarcoma requiring systemic therapy

This is a multicenter, single-arm, proof-of-concept Phase 2 clinical trial enrolling patients 18 years of age and older with histologically confirmed classic or endemic Kaposi's sarcoma requiring systemic therapy
.

Subjects received pembrolizumab (200 mg) every 3 weeks for 6 months (8 cycles) or experienced severe toxicity

Treatment response in all patients

Between July 2, 2018, and December 16, 2019, we screened a total of 30 patients, of whom 17 (8 classic Kaposi's sarcoma, 9 endemic Kaposi's sarcoma) were eligible for inclusion
.

After a median follow-up of 20.

20.

HLA-B HED levels in patients with and without remission

Treatment-related adverse events occurred in 13 (76%) patients, including two grade 3 adverse events (1 acute cardiac decompensation and 1 granulomatous reaction)
.

Two (12%) patients discontinued study treatment early due to grade 3 acute reversible cardiac decompensation and grade 2 pancreatitis, and one additional patient had a grade 3 granulomatous reaction in the mediastinal lymph nodes requiring steroids and methotrexate

This prospective study is the first to evaluate the efficacy of PD-1 blockade in classical or endemic Kaposi's sarcoma
.

The results of this study showed that pembrolizumab exhibited promising antitumor activity in patients with this type of Kaposi's sarcoma, with a good safety profile

Pembrolizumab has shown promising antitumor activity in such Kaposi sarcoma patients, and with good safety pembrolizumab has shown promising antitumor activity in such Kaposi sarcoma patients, and good security

Original source:

Julie Delyon, et al.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.